{"organizations": [], "uuid": "e448287ff54d943c32f2a07592ba18bb8e8fd912", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://feeds.reuters.com/reuters/companyNews", "section_title": "Reuters: Company News", "url": "https://www.reuters.com/article/brief-selecta-biosciences-says-expects-t/brief-selecta-biosciences-says-expects-to-report-initial-results-for-phase-2-clinical-trial-of-sel-212-in-chronic-severe-gout-in-april-2018-idUSFWN1P30QM", "country": "US", "domain_rank": 408, "title": "BRIEF-Selecta Biosciences Says Expects To Report Initial Results For Phase 2 Clinical Trial Of SEL-212 In Chronic Severe Gout In April 2018", "performance_score": 0, "site": "reuters.com", "participants_count": 0, "title_full": "", "spam_score": 0.0, "site_type": "news", "published": "2018-01-08T15:44:00.000+02:00", "replies_count": 0, "uuid": "e448287ff54d943c32f2a07592ba18bb8e8fd912"}, "author": "", "url": "https://www.reuters.com/article/brief-selecta-biosciences-says-expects-t/brief-selecta-biosciences-says-expects-to-report-initial-results-for-phase-2-clinical-trial-of-sel-212-in-chronic-severe-gout-in-april-2018-idUSFWN1P30QM", "ord_in_thread": 0, "title": "BRIEF-Selecta Biosciences Says Expects To Report Initial Results For Phase 2 Clinical Trial Of SEL-212 In Chronic Severe Gout In April 2018", "locations": [], "entities": {"persons": [], "locations": [{"name": "methylmalonic", "sentiment": "none"}], "organizations": [{"name": "sec", "sentiment": "none"}, {"name": "acidemia", "sentiment": "none"}, {"name": "selecta biosciences inc", "sentiment": "none"}, {"name": "selecta biosciences", "sentiment": "none"}, {"name": "reuters", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "#Market News January 8, 2018 / 1:45 PM / in 14 minutes BRIEF-Selecta Biosciences Says Expects To Report Initial Results For Phase 2 Clinical Trial Of SEL-212 In Chronic Severe Gout In April 2018 Reuters Staff 1 Min Read \nJan 8 (Reuters) - Selecta Biosciences Inc: \n* SELECTA BIOSCIENCES SAYS EXPECTS TO REPORT INITIAL RESULTS FOR PHASE 2 CLINICAL TRIAL OF SEL-212 IN CHRONIC SEVERE GOUT IN APRIL 2018 - SEC FILING \n* SELECTA BIOSCIENCES - EXPECTS TO SUBMIT INVESTIGATIONAL NEW DRUG APPLICATION FOR SEL-302 IN METHYLMALONIC ACIDEMIA IN 2019 Source text ( bit.ly/2EnEbTQ ) Further company coverage:", "external_links": [], "published": "2018-01-08T15:44:00.000+02:00", "crawled": "2018-01-08T16:12:17.052+02:00", "highlightTitle": ""}